Inclusion Criteria:

Patients treated with plerixafor who have 1 or more of the following:

- Background disease other than lymphoma or multiple myeloma (MM)

- Are younger than 18 years of age.

- Received transplant using ex vivo plerixafor-mobilised cells (umbilical cord cell,
peripheral blood (PB), bone marrow (BM) cell collection)

- Received treatment with plerixafor alone (i.e., without granulocyte colony
stimulating factor (G-CSF))

- Contraindication for G-CSF

- Transplants using plerixafor-mobilised cells from allogeneic donor

- Received transplant using plerixafor-mobilised bone marrow cells

- Routes of plerixafor administration other than subcutaneous

- Patients whose cells do not mobilize poorly

- Other

Exclusion Criteria:

- Adults diagnosed with lymphoma or multiple myeloma (MM) and have been treated with
plerixafor according to the European Union (EU) label.